Arcturus Therapeutics Holdings

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARCT and other ETFs, options, and stocks.

About ARCT

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. 

CEO
Joseph E. Payne
CEOJoseph E. Payne
Employees
111
Employees111
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2013
Founded2013
Employees
111
Employees111

ARCT Key Statistics

Market cap
209.97M
Market cap209.97M
Price-Earnings ratio
-2.16
Price-Earnings ratio-2.16
Dividend yield
Dividend yield
Average volume
376.60K
Average volume376.60K
High today
$7.29
High today$7.29
Low today
$6.15
Low today$6.15
Open price
$6.43
Open price$6.43
Volume
928.00K
Volume928.00K
52 Week high
$24.17
52 Week high$24.17
52 Week low
$5.50
52 Week low$5.50

Stock Snapshot

The current Arcturus Therapeutics Holdings(ARCT) stock price is $7.29, with a market capitalization of 209.97M. The stock trades at a price-to-earnings (P/E) ratio of -2.16.

On 2026-08-07, Arcturus Therapeutics Holdings(ARCT) stock moved within a range of $6.15 to $7.29. With shares now at $7.29, the stock is trading +18.5% above its intraday low and 0.0% below the session's peak.

Trading volume for Arcturus Therapeutics Holdings(ARCT) stock has reached 928K, versus its average volume of 376.6K.

Over the past 52 weeks, Arcturus Therapeutics Holdings(ARCT) stock has traded between a high of $24.17 and a low of $5.50.

Over the past 52 weeks, Arcturus Therapeutics Holdings(ARCT) stock has traded between a high of $24.17 and a low of $5.50.

ARCT News

Investing.com 17h
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view - Investing.com

...

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view - Investing.com
TipRanks 21h
Arcturus Therapeutics reports Q2 EPS (84c), consensus ($1.03)

Reports Q2 revenue $2.96M, consensus $3.12M. The company said, “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with...

Analyst ratings

77%

of 13 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

People also own

Based on the portfolios of people who own ARCT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.